Tag: Tablets
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America

Mavenclad (Cladribine Tablets) Receives First Approval in Latin America

DARMSTADT, Germany, February 26, 2018 /PRNewswire/ -- Not intended for U.K./U.S. based media  - First oral short-course treatment for highly active relapsing ...

Lees verder
Merck Receives Approval (Updated Registration) for Mavenclad (Cladribine Tablets) in Australia

Merck Receives Approval (Updated Registration) for Mavenclad (Cladribine Tablets) in Australia

DARMSTADT, Germany, December 7, 2017 /PRNewswire/ -- Not intended for U.K./U.S. based media   - First treatment in relapsing-remitting multiple sclerosis (RRMS) to ...

Lees verder
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

DARMSTADT, Germany, December 4, 2017 /PRNewswire/ -- - First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in ...

Lees verder
European Commission Grants Approval for Mavenclad (Cladribine Tablets)

European Commission Grants Approval for Mavenclad (Cladribine Tablets)

DARMSTADT, Germany, August 25, 2017 /PRNewswire/ -- - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in ...

Lees verder
Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS

Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS

DARMSTADT, Germany, June 26, 2017 /PRNewswire/ -- - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T ...

Lees verder
Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis

Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis

DARMSTADT, Germany, June 23, 2017 /PRNewswire/ -- - Efficacy and safety data support positive benefit/risk assessment from CHMP  - Cladribine Tablets is the ...

Lees verder
Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

DARMSTADT, Germany, June 24, 2017 /PRNewswire/ -- - New data builds on company's longstanding commitment to MS  Merck, a leading science and technology company, ...

Lees verder
BizPress.nl